People: Valneva SE (VLS.PA)
16 Sep 2019
Mr. David Lawrence has been Chief Financial Officer, Member of the Management Board of VALNEVA since August 1, 2017. He has over 25 years of experience in the pharmaceutical, biotech and vaccine industries, with a proven international track record in mid-sized to large companies and small biotech start-ups. His tested leadership experience as a CFO in the Lifesciences sector spans across finance and accounting, mergers and acquisitions, fund raising and investor relations. He served as CFO in a dual-listed (LSE and NASDAQ) vaccine biotech company (Acambis plc, acquired by sanofi in 2008) and was Vice President of Finance & Business Development for Chiron Vaccines, a division of Chiron Corporation which was acquired by Novartis in 2005. Prior to these roles, he held senior finance positions at GlaxoSmithKline including Vice President of Financial Management in Research and Development. He is currently also Board Member at Valneva Sweden AB, Vaccines Holdings Sweden and Valneva Canada Inc., among others.
|Total Annual Compensation, EUR||316,432|
|Restricted Stock Award, EUR||--|
|Long-Term Incentive Plans, EUR||--|
|All Other, EUR||56,194|
|Fiscal Year Total, EUR||372,626|